Clinical trials: PET/CT Imaging
Breast Cancer
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
The investigators plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study in breast cancer patients to observe the binding of the tracer to tumor lesions and evaluate CD73 expression.
- Trial name
- NCT06411678
- Testing
- 68GA-DOTA-dPNE
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer (Adenocarcinoma)
Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
The introduction of PSMA diagnostics and therapy has fundamentally changed the treatment management of prostate cancer and has significantly replaced other clinical and radiological diagnostic methods.
- Trial name
- NCT06820333
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Neuroendocrine Tumors
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).
- Trial name
- NCT03278275
- Testing
- One injection of 68Ga-NOTA-AE105, PET/CT
- Where
- Denmark
- Volunteers
- 116 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Head and Neck Cancer
Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer
Head and neck cancer (HNC) is the 6th most common cancer worldwide. In the last decade, there has been made substantial improvements in diagnosis, staging and treatment of HNC.
- Trial name
- NCT02965001
- Testing
- 68Ga-NOTA-AE105
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors .
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, Estrogen-receptor-negative Breast Cancer
- Trial name
- NCT05541367
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tongji Hospital
Breast Cancer
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
Patients with known or suspected, in the opinion of an investigator, primary or metastatic breast cancer may be eligible for this study. Up to 45 evaluable participants may undergo study imaging in this protocol.
- Trial name
- FTT 2 (NCT03846167)
- Testing
- Imaging Drug FluorThanatrace (FTT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Ocular Melanoma, Choroidal Melanoma
Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone
Patients diagnosed with ocular melanoma consent to participate in the study. Combined PET/CT scans of the whole body are performed at baseline, three months later, and six months after that for a total of three combined scans in…
- Conditions
- Ocular Melanoma, Choroidal Melanoma, Uveal Melanoma
- Trial name
- NCT00351728
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostatic Neoplasms, Prostate Cancer
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
This investigator-initiated, prospective study evaluates the diagnostic utility of rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with biopsy-proven, low-risk or favorable intermediate-risk prostate…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT07285057
- Testing
- rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Healthy Volunteer, Malaria
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Background: Malaria is a serious disease caused by parasites spread by mosquitoes. To better diagnose and treat malaria, researchers need to learn more about where the parasites go when they enter a person's body.
- Trial name
- NCT07859800
- Testing
- 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasma Cell Disorders, Multiple Myeloma (MM)
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma.
- Trial name
- NCT07660939
- Testing
- GPRC5D-Targeted PET/CT Imaging
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
PET-CT, Lymphoma
PET-CT in Lymphoma Among the Eldery
This study investigates PET-CT imaging patterns and metabolic parameters in elderly patients (≥60 years) diagnosed with lymphoma, aiming to enhance diagnostic accuracy and prognosis using 18F-FDG PET/CT scans.
- Conditions
- PET-CT, Lymphoma, Elderly, Metabolic Parameters
- Trial name
- NCT07259941
- Volunteers
- 63 people
- Sponsor
- Assiut University
Multiple Myeloma (MM)
Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
This study intends to employ 68Ga-NOTA-BCMA nanobody PET/CT imaging in patients with multiple myeloma to evaluate the feasibility of this technique for myeloma assessment, analyze the correlation between 68Ga-NOTA-BCMA nanobody…
- Trial name
- NCT07353554
- Testing
- 68Ga-BCMA nanobody PET/CT, 18F-FDG PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Melanoma
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
The main purpose of this study is to investigate the utility of the new investigational imaging agent ⁸⁹Zr Df-IAB22M2C (CD8 PET/CT tracer) to monitor CD8 T-cell expansion and trafficking within tumors and associated tissues in…
- Trial name
- NCT04955262
- Testing
- Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
- Where
- 3 sites in United States
- Sponsor
- Nektar Therapeutics
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
68Ga- and 18F-CAIX PET Imaging Study
This exploratory clinical imaging study will evaluate the safety, tolerability, biodistribution, lesion detection, and tumor uptake characteristics of 68Ga- and 18F-labeled carbonic anhydrase IX (CAIX)-targeted positron emission…
- Conditions
- Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Renal Tumor
- Trial name
- CAIX-PET (NCT07875946)
- Testing
- 68Ga-CAIX PET/CT, 18F-CAIX
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Knowledge
Knowledge and Attitudes About Advanced Maxillofacial Imaging in Dental Professionals
Introduction: Advanced maxillofacial imaging techniques, such as CBCT, CT, MRI, and hybrid modalities (PET/CT and SPECT/CT), have transformed diagnosis and treatment planning in dentistry.
- Trial name
- KAAMI (NCT07651969)
- Testing
- Submit a questionnaire
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Barcelona
Patients With Gastroenteropancreatic Neuroendocrine Tumors
TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
Evaluation of the diagnostic performance of PET / CT with 68Ga-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in routine clinical practice (octreoscan ® ; multiphase SPECT / CT…
- Trial name
- 68-DOTANOC-GEP (NCT01747096)
- Testing
- 68-Ga-DOTANOC
- Where
- 5 sites in France
- Volunteers
- 130 people
- Sponsor
- Nantes University Hospital
Non-Small Cell Lung Cancer
Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer
Radiation therapy is an important part of the treatment for lung cancer when treatment intent is for cure. Radiation is a local modality of treatment, that is, it only treats the area that the radiation can target.
- Trial name
- NCT00221169
- Testing
- Surgical resection
- Where
- 2 sites in Canada
- Volunteers
- 31 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre
Cancer, Solid Malignant Tumors
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are anticipated given the diagnostic and non-invasive, 'ex vivo' nature…
- Conditions
- Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC
- Trial name
- NCT06915454
- Testing
- Intra-op PET/CT Specimen Scanner
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Prostate Cancer
Prostate MRI and Pylarify PSMA PET/CT
This is a voluntary research study to find out how using technology including advanced magnetic resonance imaging (MRI) and prostate-specific membrane antigen - positron emission tomography (PSMA-PET) scan imaging, in addition to…
- Trial name
- NCT05568537
- Testing
- Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)
- Sponsor
- Corewell Health East
COVID-19, SARS-CoV-2 Infection
PET/CT Imaging in COVID-19 Patients
This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.
- Trial name
- NCT04376593
- Testing
- 18F-αvβ6-BP
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, Davis